There is a major need to construct safe molecular adjuvants in new mucosal vaccine development, including those designed to protect from Category A. pathogens and exotoxins. Previous work on this grant focused on defining murine nasal-associated lymphoreticular tissues (NALT) as inductive sites by use of novel nontoxic derivatives of the classical mucosal adjuvant cholera toxin (CT). In addition, we have assessed regulatory cytokines and chemokines in these studies to characterize NALT-based mucosal immunity. These studies have also included characterization of human NALT, e.g., the tonsils and adenoids for both HIV infection as well as for optimal development of mucosal and systemic immunity to prevent sexual transmission of HIV. A total of five original Specific Aims were successfully addressed. The events of September 11, 2001 and the aftermath involving anthrax-tainted letters has led to important new initiatives to assess mucosal immunity to Bacillus anthracis and its three part exotoxin. For this reason, we have chosen to study murine NALT-based mucosal immunity to anthrax using the ADP-ribosylation deficient, molecular mutants of CT and chimeras consisting of A subunit of CT and B subunits of Escherichia coil labile toxin (LT). In this renewal grant, we have proposed five Specific Aims, which when completed, will provide essential new information regarding induction of and the functions for mucosal secretory IgA (S-IgA) and serum IgG subclass and IgA antibodies (Abs) in protection from anthrax, both in vitro and in vivo. The first Specific Aim will compare nontoxic mCTs with native CT given with protective antigen (PA) for induction of protective S-IgA Abs. The second Specific Aim will characterize a new panel of monoclonal anti-PA Abs (mAbs) which include all four IgG subclasses, IgE and IgA. The third Specific Aim will employ a newly developed Brevibacillus expression system to produce mCTs and mCT-A / LT-B chimera adjuvants and PA fusion protein as a potential nasal vaccine to protect from inhalational anthrax. The fourth Specific Aim will establish in vitro respiratory epithelial cells with sensitivity to the exotoxin of anthrax for in vitro studies of S-IgA anti-PA mAbs for neutralization of anthrax exotoxin. The last Specific Aim will establish an in vivo model of nasal administration of anthrax components for development of a method to assess nasal anthrax toxicity and mucosal immunity. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043197-08
Application #
6872948
Study Section
Special Emphasis Panel (ZRG1-SSS-F (01))
Program Officer
Zou, Lanling
Project Start
1998-03-15
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
8
Fiscal Year
2005
Total Cost
$362,500
Indirect Cost
Name
University of Alabama Birmingham
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Boyaka, Prosper N (2017) Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems. J Immunol 199:9-16
Martin, Tara L; Jee, Junbae; Kim, Eunsoo et al. (2017) Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins. Vaccine 35:2511-2519
Terrazas, Cesar; Varikuti, Sanjay; Kimble, Jennifer et al. (2016) IL-17A promotes susceptibility during experimental visceral leishmaniasis caused by Leishmania donovani. FASEB J 30:1135-43
Nair, Manoj S; Lee, Marianne M; Bonnegarde-Bernard, Astrid et al. (2015) Cry protein crystals: a novel platform for protein delivery. PLoS One 10:e0127669
Jee, J; Bonnegarde-Bernard, A; Duverger, A et al. (2015) Neutrophils negatively regulate induction of mucosal IgA responses after sublingual immunization. Mucosal Immunol 8:735-45
Bonnegarde-Bernard, Astrid; Jee, Junbae; Fial, Michael J et al. (2014) Routes of allergic sensitization and myeloid cell IKK? differentially regulate antibody responses and allergic airway inflammation in male and female mice. PLoS One 9:e92307
Bonnegarde-Bernard, A; Jee, J; Fial, M J et al. (2014) IKK? in intestinal epithelial cells regulates allergen-specific IgA and allergic inflammation at distant mucosal sites. Mucosal Immunol 7:257-67
Cormet-Boyaka, Estelle; Jolivette, Kalyn; Bonnegarde-Bernard, Astrid et al. (2012) An NF-?B-independent and Erk1/2-dependent mechanism controls CXCL8/IL-8 responses of airway epithelial cells to cadmium. Toxicol Sci 125:418-29
Duverger, Alexandra; Carré, Jeanne-Marie; Jee, Junbae et al. (2010) Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant. J Immunol 185:5943-52
Fukuiwa, Tatsuya; Sekine, Shinichi; Kobayashi, Ryoki et al. (2008) A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 26:4849-59

Showing the most recent 10 out of 63 publications